Last reviewed · How we verify
Dilaudid Injectable Product
Dilaudid Injectable Product is a Opioid agonist Small molecule drug developed by University of California, Davis. It is currently FDA-approved for Moderate to severe acute pain, Severe chronic pain in opioid-tolerant patients, Postoperative pain. Also known as: Hydromorphone.
Dilaudid (hydromorphone) is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and sedation.
Dilaudid Injectable Product is a small molecule used to treat various conditions, including pain following thoracotomy surgery, post-surgical pain, and acute pain. It is administered through interventions such as neuraxial analgesia and regional block, and has also been studied for use in opioid-use disorder.
At a glance
| Generic name | Dilaudid Injectable Product |
|---|---|
| Also known as | Hydromorphone |
| Sponsor | University of California, Davis |
| Drug class | Opioid agonist |
| Target | Mu opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydromorphone is a semi-synthetic opioid derived from morphine that acts as a mu opioid receptor agonist. By binding to mu receptors in the brain and spinal cord, it modulates pain perception and produces analgesic effects. The injectable formulation allows for rapid onset of action and is used for acute and severe pain management in clinical settings.
Approved indications
- Moderate to severe acute pain
- Severe chronic pain in opioid-tolerant patients
- Postoperative pain
Common side effects
- Respiratory depression
- Sedation
- Nausea
- Constipation
- Dizziness
- Hypotension
Key clinical trials
- Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (PHASE3)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (PHASE2)
- Opioid-Sparing Joint Replacement (PHASE3)
- Pectoralis and Serratus Muscle Blocks (PHASE4)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section (PHASE4)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dilaudid Injectable Product CI brief — competitive landscape report
- Dilaudid Injectable Product updates RSS · CI watch RSS
- University of California, Davis portfolio CI
Frequently asked questions about Dilaudid Injectable Product
What is Dilaudid Injectable Product?
How does Dilaudid Injectable Product work?
What is Dilaudid Injectable Product used for?
Who makes Dilaudid Injectable Product?
Is Dilaudid Injectable Product also known as anything else?
What drug class is Dilaudid Injectable Product in?
What development phase is Dilaudid Injectable Product in?
What are the side effects of Dilaudid Injectable Product?
What does Dilaudid Injectable Product target?
Related
- Drug class: All Opioid agonist drugs
- Target: All drugs targeting Mu opioid receptor (OPRM1)
- Manufacturer: University of California, Davis — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe acute pain
- Indication: Drugs for Severe chronic pain in opioid-tolerant patients
- Indication: Drugs for Postoperative pain
- Also known as: Hydromorphone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing